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Abstract Contemporary cancer management has in-
creased the overall number of cancer survivors, but
cardiotoxicity remains a subject of concern, which is a
major cause of noncancer mortality among survivors.
Among the potential cardiovascular complications, left
ventricular (LV) systolic dysfunction is a poor prognostic
factor. The importance of its early detection is based on
the principle that the likelihood of response to heart fail-
ure (HF) treatment is temporally related to the initiation of
HF treatment. For these reasons, cardiac monitoring is
commonly applied in general practice, based on serial
measurements of LV ejection fraction (LVEF); transtho-
racic echocardiography (TTE) is generally used.
However, the LVEF, as a diagnostic and predictive param-
eter, has significant limitations, which calls for more ef-
fective multimodality imaging strategies. This approach
requires further study, but there is increasing available
data in the literature, encouraging the combination of
multimodality imaging parameters and techniques for ear-
ly cancer therapeutic-related cardiac dysfunction
(CTRCD) detection.
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Introduction—Scope of the Problem
The multidisciplinary specialty of cardio-oncology is focused
on the cardiovascular care of patients with cancer either before
or during the course of therapy, or after the completion of
treatment [1•]. The two disciplines of cardiovascular and on-
cologic disease share common points; both are the leading
causes of death in the Western world and have some poten-
tially overlapping risk factors. The development of effective
screening, alongside advances in cancer therapy, has resulted
in a 20% decline of cancer mortality [2]. However, the price to
be paid for such success is the increasing potential for anti-
cancer therapy toxicity. Cardiotoxicity can encompass a broad
range of effects: myocardial injury leading to symptomatic or
asymptomatic heart failure (HF) with preserved or reduced left
ventricular ejection fraction (LVEF), arrhythmias, myocardial
ischemia, hypertension, venous thrombotic complications,
and metabolic complications. These sequelae can potentially
transform cancer treatment into a chronic cardiovascular dis-
ease [3]. At present, cardiotoxicity has been associated with
anthracyclines, monoclonal antibodies, tyrosine kinase inhib-
itors, proteasome inhibitors, anti-angiogenesis agents, and im-
munotherapy agents [4]. A classification system has been pro-
posed to distinguish drugs that have the potential to induced
irreversible cardiac damage (type I) versus drugs that predom-
inantly induce reversible dysfunction (type II) [5]. The agents
classically associated with type I cardiotoxicity include
anthracyclines, whereas the characteristic agent for type II
toxicity is trastuzumab. Anthracycline-induced HF conveys
a very poor prognosis; compared with idiopathic cardiomyop-
athy, the survival of patients with cardiomyopathy due to
doxorubicin is significantly worse (hazard ratio, 2.64; 95%
confidence interval, 1.35 to 5.17; P = 0.005) [6]. This high
mortality can be partially attributed to noncardiac causes, but
distinct outcomes related to advanced therapies for end-stage
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HF in this patient population has been demonstrated due to
unique demographic characteristics and comorbidities [7].
Beyond the risk of symptomatic HF, a substantial proportion
of patient can experience asymptomatic changes in LVEF.
This cancer therapeutic-related cardiac dysfunction
(CTRCD) is reported in 2–3% in randomized trials on breast
cancer women treated with anthracyclines and trastuzumab
but can reach up to 26% in observational studies [8]. There
is data to suggest the potential irreversibility of LV dysfunc-
tion despite the discontinuation of the cardiotoxic agent, and
the likelihood of recovery has been linked to early introduc-
tion of HF therapy. Therefore, there is growing interest in
strategies in detecting early CTRCD [9]. Currently, the gener-
ally accepted method to monitor and detect LV systolic dys-
function during the administration of cardiotoxic agents is the
serial measurement of LVEF. Historically, multiple gate acqui-
sition (MUGA) scintigraphy have been used for years with
excellent accuracy and reproducibility [10], but has become
less utilized in favor of echocardiography. Echocardiography
is radiation free, which is of importance considering the spe-
cific need of serial monitoring, and offers the great advantage
of a complete cardiac evaluation, including assessment of he-
modynamic function, valvular function, pericardial disease,
and cardiac chamber (i.e., atria, ventricles) size and function.
In addition, its recent technological progress, with the appear-
ance of real-time three-dimensional (3D) echocardiography
and echography-dedicated contrast agents, has made this in-
creasingly the more preferred technique in all patients before
and during cancer treatment.
Cardiotoxicity Definition
Providing a precise definition of cardiotoxicity is critical,
since it could influence the interruption or modification of
cancer treatment planning. The ideal definition should be
based on one or eventually more parameters that can be easily
and noninvasively assessed, with low cost and high accuracy
and reproducibility.
LVEF has been until now the only used parameters for
cancer therapeutic-related cardiac dysfunction definition.
The heterogeneity of LVEF cutoff values used for the diag-
nostic criteria of CTRCD reported in the literature resulted in
difficulty comparing and harmonizing findings across studies.
In a joint position paper, the American Society of
Echocardiography (ASE) and the European Association of
Cardiovascular Imaging (EACVI) recommended a homoge-
neous CTRCD definition as a decrease of the LVEF of >10
percentage points, to a value <53%, confirmed by a repeated
study 2 to 3 weeks after the first diagnostic imaging study
[11••]. This definition no longer takes into account signs and
symptoms of HF, as it has previously been the case.
However, LVEF, as a diagnostic and predictive parameter,
has significant limitations. LVEF is affected by loading con-
ditions and is of limited accuracy for detecting subclinical
myocardial dysfunction, and can be prone to significant inter-
observer and intraobserver variability. Indeed, diagnosing a
CTRCD based on a decrease of LVEF could be late, with
potential irreversible damage to the heart already done; thus,
a more precise definition of cardiotoxicity, including criteria
for subclinical LV dysfunction, is warranted. It may be neces-
sary to include combination of imaging criteria and circulating
biomarkers, employed as a multimodality strategy as an ap-
proach throughout the continuum of cancer care—from risk
stratification of cardiotoxicity prior to treatment, to detection
of early cardiotoxicity during treatment, and for surveillance
of late cardiotoxicity in survivors. The different methods of
imaging as well as circulating biomarkers will be discussed,
along with a review of the literature regarding their utility for
the detection of cardiotoxicity.
Imaging Techniques
Echocardiography
Transthoracic echocardiography (TTE) is currently the corner-
stone in the cardiac imaging evaluation of patients before,
during, and after anticancer therapy. It is inexpensive, readily
available, reproducible, noninvasive, with no ionizing radia-
tion exposure, and is also safe in patients with renal functional
impairment. Furthermore, a complete TTE examination of-
fers, in a single time, information on LV geometry and LV
systolic and diastolic functions, together with an evaluation
of valvular function and the pericardium. A recommended
cardio-oncology echocardiogram protocol has been recently
proposed by the ASE/EACVI [11••]. The calculation of LVEF
should be performed at each time with the best method avail-
able in a given echocardiography lab. According to the above
recommendations, the two-dimensional echocardiography
(2DE) method of choice for LV volumes quantification and
LVEF calculation is the modified biplane Simpson’s tech-
nique (Fig. 1). Normal LVEF using biplane method of disks
is 63 ± 5% and LVEF in the range of 53 to 73% is classified as
normal.
However, accurate LVEF quantification can be limited, not
only by the conceptual limitations of the LVEF but also by
technical considerations; some issues include the non-
universally applicable geometric assumptions of the 2D LV
model, the requirement of good image quality (especially en-
docardial border delineation), optimal apical views alignment
(to identify the true apex), and the load-dependent nature of
LVEF assessment, which can be potentially problematic in
cancer patients. The specific cardio-oncology requirement of
sequential evaluation of LVEF is therefore confronted to
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proven significant variability. The sources of variability have
been classified as interobserver variability (measurements
made on the same images by different investigators),
intraobserver variability (repeated measurements made by an
individual investigator on the same images), and temporal
variability (repeated echo recordings). In a head to head com-
parison, temporal variability has been shown to represent the
dominant component of variation [12]. Indeed, small differ-
ences in angulation and placement of the transducer during
serial echo recordings may influence measurements of LV
dimensions. However, the real life monitoring of LVEF during
follow-up of patient faces the interobserver test-retest variabil-
ity, which is the variability observed between two studies at
different time points with measurements performed by differ-
ent individuals. For 2DE LVEF assessment, the interobserver
test-retest variability is very high with minimal detectable dif-
ference in EF of 13% [13], explaining why 2DE LVEF gen-
erally fails to detect small variations attributable to
cardiotoxicity.
Newer echocardiography techniques, using contrast echo-
cardiography or 3D technology, have resulted in significant
improvement in the accuracy of LVEF assessment. Contrast
echocardiography is the recommended option when two con-
tiguous LV segments from any apical views are not well seen
[14, 15]. It increases the accuracy of volume assessment in
case of poor acoustic window, but it has no demonstrated
interest in case of good images quality (lower reproducibility
and higher temporal variability) [13]. The potential of 3D
echocardiography (3DE) is of upmost interest in the field of
cardio-oncology. Indeed, at a time point, 3DE LVEF, com-
pared to 2DE LVEF, has been demonstrated of higher accura-
cy and of closer correlation to the reference LVEF obtained
with cardiac magnetic resonance (CMR) [16, 17]. In an ideal
3DE assessment of LVEF, the potential errors associated with
geometric assumptions, foreshortened views, or suboptimally
acquired orthogonal apical two- and four-chamber views are
not present, as it is the case with 2DE volume calculations.
Furthermore, 3DE LVEF has been demonstrated to have an
improved accuracy over 2DE in detecting LVEF <50% [18],
which is frequently the chosen cutoff value to warrant in-
creased cardiac monitoring during the administration of anti-
cancer agents associated with known cardiotoxicity. 3DE has
been showed to be feasible, accurate, and reproducible for
assessing changes in LV volumes and LVEF when compared
with CMR, in women receiving adjuvant trastuzumab after
doxorubicin for breast cancer [19]. The reproducibility of
2DE and 3DE, with and without contrast agents, has been
studied in the breast cancer population, with non-contrast
3DE LVEF demonstrating lower temporal variability [13]. It
is recommended that 3DE LVEF should be the preferred tech-
nique for monitoring LV function and detecting CTRCD in
patients with cancer [11••] (Fig. 2). However, it is important to
consider that 3DE LVEF has the same conceptual limitations
as 2D LVEF assessment.
Ultrasound deformation imaging has generated a great deal
of interest in detecting subclinical LV dysfunction, which is
obtained preferentially by speckle tracking, has been proposed
based on its higher sensitivity in detecting subtle systolic LV
variation. Also, it is less load dependent than LVEF and may
have higher prognostic value. In a multicenter study compar-
ing echocardiographic parameters in patients with HF, global
longitudinal strain (GLS) assessment, a parameter evaluating
longitudinal aspect of myocardial contraction using deforma-
tion imaging, appeared to have a higher and more reliable
Fig. 1 The 2DE method of
choice for LV volumes
quantitation is the biplane method
of disks summation (modified
Simpson’s rule). Volume
measurements are derived from
tracings of endocardial borders in
the apical four-chamber (a, b) and
two-chamber (c, d) views, in end-
diastolic (a, c) and end-systolic
(b, d) frames. The LVEF is then
calculated: LVEF = (LVEDV –
LVESV) / LVEDV. LVEDV LV
end-diastolic volume, LVESV LV
end-systolic volume
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prognostic value than LVEF for the prediction of cardiac
events and cardiac deaths [20]. 2D speckle tracking strain
has already been evaluated in studies for a total of more than
700 patients concomitantly to the administration of
cardiotoxic anticancer agents, with encouraging results
concerning its capability to diagnose subclinical LV dysfunc-
tion of subsequent clinical relevance [21–27]. Based on these
data, serial strain measurements are suggested during antican-
cer treatment [11••]. Ideally, the measurements during chemo-
therapy should always be compared with the baseline value. A
relative reduction of GLS of less than 8% from baseline does
not appear to be clinically significant, whereas a decrease of
more than 15% from baseline is likely to be abnormal and
predictive of subsequent LVEF decrease and meeting criteria
for CTRCD [11••]. If baseline GLS has not been documented,
a value of < −19% is also predictive of CTRCD. The nadir of
the change of GLS has been noted 9 months after the initiation
in the case of anthracyclines administration in breast cancer
patients treated with anthracycline-trastuzumab regimen [27].
Importantly, the reported GLS should be notified with speci-
fication of the used echocardiography machine and software,
and with the same vendor-specific echo machine used during
follow-up. If the GLS is not measured, then the medial and
lateral tissue Doppler systolic velocity (s’) and mitral annular
plane systolic excursion (MAPSE) should be reported.
Cardiac Magnetic Resonance
Magnetic resonance imaging (MRI) has gained importance
for cardiovascular imaging thanks to advances in both
hardware and software. ECG gating and respiratory motion
suppression technologies are used to optimize the acquisition
of high-quality cross-sectional images of the heart, with spa-
tial resolution of 1–2 mm and temporal resolution of 25–
50 ms. In addition, the application of MRI to the cardiovascu-
lar imaging offers a wide field of view and flexible scanning
planes. CMR is therefore now considered as the noninvasive
reference method for the assessment of cardiac volumes, func-
tion, and composition, and for the diagnosis of ischemia and
research of myocardial viability. CMR potential is dependent
on different techniques, including manipulating of pulse se-
quence parameters and generating different types of soft-
tissue contrast.
An increasing number of studies have examined CMR ca-
pabilities for the evaluation of anticancer therapeutics-induced
myocardial remodeling, including LVEF surveillance during
anticancer treatment. A CMR technique for the assessment of
LV morphology and function is cine steady-state free preces-
sion (SSFP), which analyzes a set of contiguous short-axis
cine sequences from the atrioventricular plane to the apex, in
which the blood pool and myocardium has a bright and dark
appearance, respectively. This 3D volumetric LV coverage,
with high contrast-to-noise ratios, offers images with excellent
discrimination of endocardial and epicardial borders, allowing
LVEF and mass quantification without the need of geometric
assumption, and risk of incomplete sampling of ventricular
volumes. Therefore, CMR has been demonstrated to be supe-
rior to 2DE for the quantification of LVEF with higher inter-
study reproducibility [28] and has progressively become the
gold standard for accurate and reproducible quantification of
Fig. 2 3D image acquisition
focuses primarily on including the
entire left ventricle within the
pyramidal 3D data set. The
software then tracks end-diastolic
and end-systolic volume. One of
the important advantages of 3D
echocardiographic volume
measurements is that they do not
rely on geometric assumptions. In
patients with good image quality,
3D echocardiographic
measurements are accurate and
reproducible and should therefore
be used when available and
feasible
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LVEF [29]. Importantly, 2DE and CMR have been compared
for the screening of CTRCD in adult survivors of childhood
cancer exposed to anthracyclines or left chest radiation [18].
Compared with CMR, 2DE (biplane method) had a sensitivity
of 25% and a false-negative rate of 75% for detection of LVEF
less than 50%. 2DE also overestimated the mean LVEF of this
population by up to 5%. Thus, CMR more accurately identi-
fied cardiomyopathies among adult survivors previously un-
diagnosed with cardiac disease using 2DE. On the other hand,
compared 3DE LVEF assessment excellent correlation was
seen compared to LVEF assessment by CMR [19]. CMR, or
alternatively 3DE, should therefore be considered for LVEF
confirmation in patients receiving anticancer treatment with a
LVEF between 50 and 59% by 2DE, as the cutoff value of
50% of LVEF remains the one used to decide to suspend or
discontinue anticancer treatment [30••].
A comprehensive 2D and 3D echocardiography is some-
times a challenge in patients with breast cancer due to loco-
regional infiltration by the tumor, mastectomy, or breast im-
plants. The use of contrast agents may be useful is those cases.
However, CMR is recommended if an accurate LVEF calcu-
lation is still not feasible with the administration of contrast.
CMR cannot be systematically recommended until now due to
important limitations: a much higher cost compared with
echocardiography, less accessibility, and individual limita-
tions (i.e., claustrophobia, ferromagnetic implants).
The interest of earlier CTRCD detection, based on a better
response to cardioprotective treatment when administered pre-
cociously, has prompted, as it has been the case for 2DE,
advances in CMR technologies that can detect myocardial
functional changes despite still preserved LVEF. Newer
CMR technologies allow the detection of subclinical myocar-
dial dysfunction, but also offer unique information on tissue
characterization, not available with other cardiovascular non-
invasive imaging techniques. Some CMR techniques seem to
have a higher value in the field of CTRCD (Table 1) than
others. For example, myocardial edema, a sign of acute myo-
cardial injury evaluated using T2 mapping, has not been as-
sociated until now with CTRCD [31, 33, 35, 36]. Thus, the
definition of cardiotoxicity warrants reassessment in light of
the advent of these newer imaging technologies.
Circulating Biomarkers
The serial measurement of serum biomarkers has been pro-
posed to address the multiple limitations of LVEF monitoring
for the early diagnosis of CTRCD. The potential of bio-
markers utilization may allow for early identification of vul-
nerable patients in the subclinical stage of CTRCD, and may
offer a more convenient, low cost method of monitoring, hav-
ing predictive value in other cardiomyopathy disease states.
However, the validation of a cutoff value correlating with
clinically significant cardiotoxicity, and the determination of
the optimal timing, frequency, and duration of testing remain
the major limitations of biomarkers, restricting currently their
routine use.
The most studied biomarkers are those whose values have
already been validated in other cardiomyopathies, namely tro-
ponins and natriuretic peptides. Cardiac troponins are sensi-
tive markers of myocardial injury with both troponin I (Tn-I)
and T (Tn-T) assays. Cardinale et al. demonstrated that the
timing and degree of Tn-I rise was predictive of developing
LV dysfunction, and also correlated with anthracycline cumu-
lative dosing [43–46]. Tn-I monitoring also served effectively
as risk stratification in their studied population; patients treat-
ed with high-dose chemotherapy who developed an increased
in Tn-I were the ones who benefited more from the initiation
of an angiotensin-converting enzyme inhibitor treatment
(enalapril), preventing LVEF decrease [47]. In addition, an
increase in Tn-I was associated with a 17.6 times increased
risk of cardiotoxicity, and emerged as the only independent
predictor of lack of recovery in LVEF despite treatment with
HF therapy, which consisted of enalapril and carvedilol up-
being titrated to maximally tolerated doses used in conven-
tional HF [48]. However, these results still need to be con-
firmed [49–51]. High-sensitive troponins assays may have a
greater interest for the detection of subclinical myocardial
damage. Sawaya et al. recently demonstrated that high-
sensitive Tn-I assays in combination with echocardiography
strain imaging increase the accuracy of early detection and
prediction of CTRCD in breast cancer patients treated with
anthracyclines and trastuzumab [22, 24]. The ASE/EACVI
consensus document recommends serial Tn-I levels be drawn
with a chemotherapy regimen potentially associated with type
I or type II toxicities or in case of their sequential administra-
tion [11••]. In the event of encountering positive biomarkers, it
is recommended to refer the patient to cardiology consultation
for further evaluation and consideration of cardioprotective
therapy. During chemotherapy administration, troponin mon-
itoring is suggested before and/or 24 h after each chemother-
apy cycle [43]. Patients with troponin elevations during ther-
apy (as defined by the cutoffs specific to the assay platform
used in the individual labs) are at a higher risk for subsequent
cardiovascular events [43].
Natriuretic peptides (B-type natriuretic peptide [BNP] and
N-terminal proBNP [NT-proBNP]) are cardiac hormones re-
leased from ventricular myocardium in response to increased
wall stress (markers of elevated LV pressure) and standard
biomarkers in clinical practice for the diagnosis and manage-
ment of HF. Natriuretic peptides biomarkers have been eval-
uated for risk stratification prior to and during therapy for
cardiotoxicity. For instance, a single baseline NT-proBNP lev-
el of 900 pg/ml or more was associated with a higher risk of
death from any cause in lymphoma patients treated with che-
motherapy [52]. Evidences advocating the interest of
Curr Oncol Rep  (2017) 19:63 Page 5 of 12  63 
natriuretic peptides monitoring during the course of chemo-
therapy exist [53–56]. A persistently increased NT-proBNP
(early after high-dose chemotherapy administration) is predic-
tive of subsequent LV dysfunction during follow-up [53, 55].
However, other studies found no correlation between natri-
uretic peptide increase and development of cardiac dysfunc-
tion in patients receiving anthracycline-based chemotherapy
[57]. Those results are explained by the difficulty in
interpreting these biomarkers among heterogeneous popula-
tions (small number of patients, various different types of
malignancies, varying chemotherapeutic regimens), using dif-
ferent natriuretic peptides (BNP, NT-proBNP, atrial natriuretic
peptide [ANP], NT-proANP), different laboratory methods,
cutoffs, sampling time, and differing follow-up duration and
endpoints. Furthermore, BNP and NT-proBNP are makers of
wall stress rather than myocardial injury. Elevations during
cancer therapy may not be as specific as troponins elevations
[58].
Finally, many emerging biomarkers, exploring different
potential mechanisms of cardiotoxicity, have been proposed
for monitoring of cardiotoxicity in recent studies [59, 60]. In a
multicenter cohort of 78 patients with breast cancer undergo-
ing doxorubicin and trastuzumab therapy, 8 potential relevant
biomarkers (high-sensitive Tn-I, high-sensitivity C-reactive
protein, NT-proBNP, growth differentiation factor-15,
myeloperoxidase [MPO], placental growth factor, soluble
fms-like tyrosine kinase receptor-1 and galectin-3) were eval-
uated at baseline and every 3 months over a follow-up period
of 15 months. The risk of cardiotoxicity was not significantly
associated with baseline levels of any of these biomarkers.
However, the early changes in Tn-I and MPO, the combina-
tion of increasing biomarkers and finally the persistence of an
increase in MPO beyond 3 months, were predictors of
cardiotoxicity risk over the duration of doxorubicin/
trastuzumab therapy [61, 62].
Multimodality Baseline and Surveillance Strategies
An approach that integrates circulating biomarkers and non-
invasive cardiac imaging parameters for baseline evaluation
and surveillance strategy may provide additive value in
predicting cardiotoxicity. This conceptual approach requires
close multidisciplinary collaboration of the oncologist and the
cardiologist in interpreting and reacting to the results of these
findings.
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Baseline Cardiac Evaluation
The baseline cardiac evaluation is very important and requires
standardization. The authors propose that such an evaluation
should be considered in every patient receiving chemotherapy
agents associated with known or suspected cardiotoxicity. It
should also be routinely performed in patients with a docu-
mented pre-existing or acquired cardiomyopathy, risk factors
of cardiac disease, >65 years old and scheduled high-dose
type I agents or combined regimens with type I and type II
agents [11••]. Baseline global cardiovascular risk assessment
should also be included, as they have been demonstrated to be
risk factors of CTRCD [30••]. The baseline cardiac evaluation
also includes a thorough medical history, physical examina-
tion, electrocardiogram, and LVEF quantification. Indeed,
LVEF remains an important screening tool. 2DE, 3DE, and
CMR quantification of LVEF show good correlation [63] but
absolute values can differ. Thus, LVEF obtained from differ-
ent imaging modalities may not be interchangeable [64]. In
routine practice, a single technique ideally should be used for
baseline assessment and follow-up studies during and after
cancer therapy [11••]. CMR should always be considered
when 2DE-derived LVEF is suboptimally visualized and/or
serially noted to have discrepant findings, particularly in pa-
tients with lower limit of normal LVEF (2DE has been known
to overestimate the LVEF in this population compared to
CMR) [18]. Borderline low baseline LVEF holds a confirmed
predictive value to identify among women treated for breast
cancer those at risk of CTRCD [65, 66]. However, a normal
baseline LVEF assessment alone does not formally exclude
the occurrence of chemotherapy-induced cardiac events: con-
gestive HF has also been reported in 2.1 and 4.2% of patients
with a baseline LVEF of ≥65% and 55–64%, respectively
[65]. If feasible (good image quality, software available), base-
line 2DE should include a baseline assessment of GLS [11••].
Finally, measurement of cardiac biomarkers—troponins and/
or natriuretic peptides—may be considered at baseline al-
though evidence supporting this strategy is still lacking
[11••, 67••].
Cardiac Monitoring During Cardiotoxic Cancer Therapy
At present, serial monitoring of LVEF remains the most fre-
quently used parameter for detecting CTRCD. Concerning
type I agents, the recommended timing for surveillance is at
the completion of therapy, particularly when the patient has an
increased risk for cardiotoxicity or consecutive treatment with
potentially cardiotoxic targeted therapies will follow [11••,
67••]. For regimens including cumulative total doxorubicin
(or equivalent) doses >240 mg/m2, an evaluation before each
additional 50 mg/m2 is strongly recommended. Additional
monitoring is finally mentioned 6 months after the completion
of anthracycline. For type II agents, LVEF assessment every
3 months is generally recommended and once after comple-
tion of treatment [67••].
However, an important additive value of effective cardiac
surveillance during chemotherapy is the detection of subclin-
ical LV dysfunction. To meet this objective, as discussed
above, LVEF assessment alone is insufficient. The authors
propose a strategy that include, in addition to LVEF assess-
ment, the GLS calculation and the baseline chosen biomarker
measurement, all for prospective comparison with baseline
data. Indeed, addition of monitored parameters via a
multimodality surveillance strategy increases sensitivity of
subclinical LV dysfunction detection [61, 62]. However, only
a few studies have explored the value of such a combined
approach for the diagnosis and risk stratification of CTRCD
(Table 2, Fig. 3). Fallah-Rad et al. conducted the first
multimodality surveillance strategy, combining biomarkers
(troponin T, CRP, and BNP) with imaging (TTE and CMR)
in breast cancer patients treated in the adjuvant setting by
anthracyclines and trastuzumab [23]. Biomarkers were not
associated with any prognostic value, along with LVEF as-
sessment, but Doppler measurement of s’, GLS, and radial
strain parameters were able to identify at 3 months follow-
up the patients that developed CTRCD at 6 months. In this
study, CMR, performed at baseline and at 12 months, docu-
mented an increase in LV volumes, a decrease in LVEF, and a
late gadolinium enhancement in the LV lateral wall in the
CTRCD group. Sawaya et al. studied a very similar popula-
tion with similar biomarkers [22]. NT-proBNP was not asso-
ciated with any predictive value but high-sensitive Tn-I at
3 months appeared as an independent predictor of
cardiotoxicity at 6 months. A combination of myocardial lon-
gitudinal strain and high-sensitive Tn-I allowed the identifica-
tion of subtle myocardial alterations and was predictive of
subsequent LVEF reduction during the routine surveillance
of patients receiving trastuzumab after anthracyclines. The
high negative predictive value of the two tests also allowed
the confident exclusion of cardiotoxicity 3 months later. In a
longer follow-up of 15 months, in a similar breast cancer
population, a GLS value of <19% and high-sensitive Tn-I
level of ≥30 pg/ml measured after anthracycline administra-
tion and before taxanes and trastuzumab infusion were predic-
tive of subsequent development of CTRCD [24]. The troponin
levels added prognostic value to GLS: if both were abnormal,
the specificity for the prediction of CTRCD increased from 73
to 93%. If both were normal, the negative predictive value
increases to 91% [24].
These studies, although limited and small in scope, support
an integrated approach for cardiac surveillance and subclinical
LV dysfunction detection in the ASE/EACVI expert consen-
sus statement [11••]. A relative percentage reduction of GLS,
with the selected cutoff value of >15%, is very likely to be
abnormal, whereas a change <8% seems not clinically signif-
icant. In regards to biomarkers, the consensus document report
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that troponins elevation, measured before and/or 24 h after
chemotherapy infusion, is associated with a higher risk of
cardiovascular events and cardiology consultation should be
considered. No specific cutoff value is given, but one must
refer to the cutoffs specific to the essay platform used in indi-
vidual labs.
Proposed Multimodality Imaging Strategies
Cardiovascular complications can be a concerning issue dur-
ing the course of cancer therapy, as cardiac side effects ad-
versely affect oncological therapy and cancer prognosis.
Current cardiac surveillance strategies are limited due to from
a lack of standardization as well as studies validating their
approaches. Patients scheduled to receive high dose of type I
agents, type II agents, or sequential chemotherapy with type I
and type II agents require a thorough, systematic, and consis-
tent approach to their cardiac evaluation which has yet to be
determined. Secondly, current CTRCD definition is based on
a decrease of the LVEF [11••], even though LVEF assessment
alone is likely insufficient, as end stage myocardial insult is
likely present by the time this manifests, particularly in type I
cardiotoxicity. While cancer survival rates have increased due
to significant advances made in treatment, efforts made to
reduce short- and long-term cardiotoxicity should be a priority

























4 43 Reduction of LVEF of ≥5% to
<55% with HF symptoms
or asymptomatic reduction




• 9/43 (21%) met the criteria of
CTRCD
• hsTn-I > 0.015 mcg/l at
3 months (p < 0.02) and
decrease in GLS at 3 months
(p < 0.02) are independent
predictors of CTRCD at
6 months
• patients who either demonstrate
a >10% decrease in GLS or
elevation in hsTn-I at 3 months
have a ninefold increase in risk











1 42 Reduction in LVEF of >10 to







• 10/42 (25%) met the criteria of
CTRCD
• no predictive value of
biomarkers
• lateral s’ <6 cm/s at 3 months is
predictive of CTRCD:
sensitivity 93%, specificity
99%, PPV 96%, NPV 98%
• a 2% reduction of GLS at
3 months is predictive of
CTRCD: sensitivity 79%,
specificity 82%, PPV 60%,
NPV 92%













4 81 Reduction of LVEF of ≥5% to
<55% with HF symptoms
or asymptomatic reduction







• 26/81 (32%) met the criteria of
CTRCD
• GLS < 19% is the only
independent predictor of
CTRCD (p = 0.0003)
• hsTn-I measurement combined
with GLS increase the
sensitivity of the biomarkers
from 74% to 87%, NPP 91%
A anthracyclines, CMR cardiac magnetic resonance, CTRCD cancer therapeutic-related cardiac dysfunction, GLS global longitudinal strain, HF heart
failure, LVEF left ventricular ejection fraction, NT-proBNP N-terminal pro-brain natriuretic peptide, NPV negative predictive value, PPV positive
predictive value, T trastuzumab, Tn-T troponin T, TTE transthoracic echocardiography, Tx taxanes, hsTn-I high-sensitive troponin I
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in ongoing research efforts [68]. Developing surveillance
strategies allowing an earlier detection of CTRCD are of ut-
most importance, and standardized care plans incorporating
multimodality imaging may potentially meet the objective of
earlier detection of myocardial dysfunction, and can lead to
earlier initiation of cardioprotective agents (beta blockers,
angiotensin-converting enzyme inhibitors, or angiotensin II
receptor blockers).
First, any strategy will depend on a standardized baseline
cardiac assessment. Concerning the cardiac imaging aspects,
the gold standard is TTE. Precise baseline LVEF measure-
ment, using 2DE or preferably 3DE, is fundamental and
GLS assessment is desirable. Biomarkers dosage is also sug-
gested. Any abnormality of these three parameters should lead
to multidisciplinary discussion between cardiologist and on-
cologist in determining surveillance frequency for
cardiotoxicity, and consideration of implementing
cardioprotective drugs, and the choice of continuing or alter-
ing cancer treatment to be at the discretion of the oncologist.
Baseline CMR is indicated if suboptimal echocardiographic
images are obtained, or of a borderline abnormal LVEF or
discrepant readings on serial studies.
The timing of surveillance using cardiac imaging and bio-
markers should be established based on cardiotoxicity profile
of the chemotherapy regimen, ideally personalized to the pa-
tient baseline cardiovascular risk [67••, 69]. The goals of treat-
ment, whether it be adjuvant, neo-adjuvant, or palliative che-
motherapy, also should determine the extent of cardiotoxicity
monitoring with ongoing weighing of risks and benefits of
continuing treatments if LV dysfunction occurs.
CTRCD definition is based on the LVEF evaluation and
this parameter should normally be numerically reported at
each evaluation. As LVEF obtained from TTE (2DE, 3DE)
and CMRmay not be interchangeable, the same imaging tech-
nique as the one chosen for baseline evaluation should be used
for surveillance. In the same time, the follow-up studies
should also report any evidence of subclinical LV dysfunction.
Available validated tools are GLS and biomarkers. GLS has
been considered to be accurate and prognostic in detecting
subclinical cardiotoxicity in patients receiving cardiotoxic
Fig. 3 Forty-six-year-old woman diagnosed with right breast cancer
(invasive ductal carcinoma) with lymph node involvement. The
anatomopathology analysis revealed triple negative carcinoma. Her
previous medical history included treated hypertension, where she was
taking olmesartan 40 mg daily and bisoprolol 2.5 mg daily, and type II
diabetes mellitus. She received neo-adjuvant chemotherapy (4 regimens
of epirubicin-cyclophosphamide followed by 12 weekly carboplatin-
paclitaxel) before undergoing right mastectomy and axillary lymph
node dissection. Histopathology revealed HER-2 positive invasive
ductal carcinoma, warranting adjuvant trastuzumab. Her baseline LVEF
was 65%. Post anthracycline 2D LVEF was 51% (a), confirmed at
3 weeks, corresponding to the definition of CTRCD. 3D LVEF was
also calculated at 51% (b), GLS was—15.7% (c), and CMR LVEF
47% (d). Trastuzumab was initiated with close monitoring of LVEF
(every 3 weeks) using multimodality approach (2DE, 3DE, and GLS)
and with cardioprotective treatment titrated to the maximal tolerated
dosage. CMR cardiac magnetic resonance, CO cardiac output, CTRCD
cancer therapeutic-related cardiac dysfunction, GLS global longitudinal
strain, LVEDV left ventricular end diastolic volume, LVEF left ventricular
ejection fraction, LVESV left ventricular end systolic volume, SV stroke
volume
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anticancer agents [21–27]. Cutoffs value for relative percent-
age reduction during surveillance which are suggestive of
clinically significant cardiotoxicity has been proposed in the
ASE/EACVI expert consensus document [11••], although fur-
ther studies are needed to validate these findings.
In regards to biomarkers, troponin levels appear to have the
best predictive value in detecting cardiotoxicity monitoring,
with the timing and the degree of the rise correlated with risk
of CTRCD [43–46]. Troponin elevations during treatment al-
so identify a high risk cohort of cancer patients who may
benefit from early cardioprotective medication [47].
Natriuretic peptides are strong predictors of elevated LV pres-
sure and HF. For subclinical LV dysfunction detection during
cancer therapy, data is inconsistent but it appears that the per-
sistence of NT-proBNP elevation during follow-up identifies
patients at higher risk of LVEF decline [53, 55].
Conclusions
In conclusion, a multimodality surveillance strategy, utilizing
both imaging and biomarkers, is ideal in accurately detecting
subclinical LV dysfunction induced by cardiotoxic chemo-
therapy. While advances in imaging technology have allowed
for more precise assessment of cardiac function, CTRCD
criteria of LV dysfunction have not been updated to include
parameters such as subclinical dysfunction, or how to accu-
rately assess LVEF using different imaging modalities. While
the most optimal approach remains to be seen and requires
prospective study, cancer patients have the potential to benefit
from earlier detection of cardiotoxicity and intervention,
allowing them to potentially continue with lifesaving
treatments.
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